Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study
https://doi.org/10.17650/1726-9776-2007-3-1-59-65
Abstract
The RTOG 85-31 study has indicated that adjuvant hormonotherapy is particularly effective in prostate cancer (PC) patients with a high Glisson score. Long-term adjuvant hormonotherapy is not warranted in patients with a total Glisson score of 2-6. Exception is patients with disseminated locally advanced tumors, in whom neoadjuvant androgenic suppression (RTOG 86-10 protocol) considerably improves the results of treatment. Long-term adjuvant hormonotherapy may be the method of choice in treating PC patients with a poor prognosis.
About the Authors
Miljenko V. Pilepich
California University, Los Angeles, School of Medicine, Los Angeles, CA
United States
M.D.
United States
M.D.
Kathryn Winter Winter
Group of Radiation Therapy in Oncology, Philadelphia, PA
United States
M.S.
United States
M.S.
Colleen A. Lawton
Wisconsin Medical College, Milluoki, WI
United States
M.D.
United States
M.D.
Robert E. Krisch
University of Pennsylvania State, Philadelphia, PA
United States
M.D.
United States
M.D.
Harvey B. Wolkov
Association of Radiology of Sacramento, Sacramento, CA
United States
M.D.
United States
M.D.
Benjamin Movsas
Fox Chase Cancer Center, Philadelphia, PA
United States
M.D.
United States
M.D.
Eugen B. Hug
Hitchcock Dartmouth Medical Center, Lebanon, NH
United States
M.D.
United States
M.D.
Sucha O. Asbell
Albert Einstein Medical Center, Philadelphia, PA
United States
M.D.
United States
M.D.
David Grignon
Whane State University, Detroit, MI
United States
M.D.
United States
M.D.
References
1. Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis — 1974;27:365—75.
2. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980.
3. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat — 1988; 16:1141—54.
4. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc — 1958;53:457—81.
5. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep — 1966; 50:163—70.
6. Cox D.R. Regression models and life tables. J R Stat Soc Series B — 1972;34:187—229.
7. Pilepich M.V., Caplan R., Byhardt R.W. et al. Phase in trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85—31. J Clin Oncol — 1997;15:1013—21.
8. Pilepich M.V., Winter K., John M.J. et al. Phase in RTOG trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys — 2001;50:1243—52.
9. Bolla M., Gonzalez D., Warde P. et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med — 1997;337:295—300.
10. Bolla M., Collette L., Blank L. et al. Long term results with immediate androgen suppression and external irradiation in pa-tients with locally advanced prostate cancer (an EORTC study): A phase IE randomized trial. Lancet — 2002; 360:103—8.
11. Lawton C.A., Winter K., Murray K. et al. Updated results of the phase in RTOG trial 85-31: Evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys — 2001;49:937—46.
12. Pilepich M.F., Krall J.M., Sarraf M. et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized com-parative trial of the Radiation Therapy Oncology Group. Urology — 1995;45:616—23.
13. Laverdiere J., Gomez J.L., Cusan L. et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer . Int J Radiat Oncol Biol Phys — 1997;37:247—52.
14. Hanks G.E., Pajak T.F., Porter A. et al. Phase in trial of longterm adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol — 2003;21: 3972—8.
15. Stege R. Potential side-effects of endocrine treatment of long duration in prostate cancer. Prostate Suppl — 2000;10:38—42.
16. Berruti A., Dogliotti L., Terrone C. et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with cancer without apparent bone metastases given androgen deprivation therapy. J Urol — 2002; 167:2361—67.
17. Ross R.W., Small E.J. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol — 2002;167:1952—56.
Review
For citations:
Pilepich M.V., K.W., Lawton C.A., Krisch R.E., Wolkov H.B., Movsas B., Hug E.B., Asbell S.O., Grignon D. Adjuvant androgenic blockade after teleradiotherapy for prostate cancer: long-term results of phase III rtog 85-31 study. Cancer Urology. 2007;3(1):59-65. (In Russ.) https://doi.org/10.17650/1726-9776-2007-3-1-59-65
Views:
290
Email this article 